Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > ProMIS making progress, don't believe the hate
View:
Post by Gbathat on Apr 13, 2021 8:41pm

ProMIS making progress, don't believe the hate

ProMIS has always been a company with tremendous technical potential and a huge potential market, but recently there have finally been some great business developments.

A group of world renowned business magnates provided $7M in financing to ProMIS and stated that their due diligence indicates the technology has tremendous potential. This investment will be used to transition PMN310 into Phase 1 clinical trials for treatment of Alzheimer's disease, one of the biggest unmet needs in the world.


https://www.globenewswire.com/news-release/2021/03/22/2197066/0/en/ProMIS-Neurosciences-Completes-US-7M-CDN-8-75M-Financing-with-Distinguished-Group-of-Boston-Based-Investors.html

Sidenote: LeBron James might become an indirect investor in ProMIS as well, haha...
https://www.bostonglobe.com/2021/03/16/sports/fenway-sports-group-adds-lebron-james-partner-approves-deal-jump-start-plan-acquire-more-teams/

One of PMNs 50-50 JV partners who is developing a COVID serology assay that rapidly analyzes and classifies antibodies is now officially taking patient referral forms for testing. The test is described as 'awaiting accreditation,' likely indicating that accreditation is actively being sought. This assay is unique in its ability to distinguish antibodies that may correlate with immunity.
https://bcneuro.ca/wp-content/uploads/2021/03/Req-2.5-March-2021.pdf

Dr. Neil Cashman, Chief Science Ofiicer of Promis, was recently featured in several media platforms for his role in responding to an unknown brain disease, and the article featured ProMIS capabilities and plans for moving several drugs into clinical trials in partnership with large pharma. https://www.med.ubc.ca/news/ubc-neuroscientist-joins-investigation-of-a-mysterious-new-brain-disease/ 

So the naysayers and trolls around here can pollute this board as much as they want.  I'll keep ignoring them and posting the good news that they cannot overshadow.  They pretend like they don't have an agenda.  They do. They rarely share any due diligence.  They just spew hate and unverified conspiracy theories.  It won't work.  Just my opinions, but with links to public articles that at partly least support them.  
Comment by farmerjane on Apr 13, 2021 9:46pm
Elliot, really look at your blog mostly about PP's and future with LeBron James. Who cares tell him to keep playing basket ball. Nothing about Partnerships, Collabarations actual science deals?  Another smoke screen by you and Eugene, and thank-you for the naysayer and troll comment as i am going to double down and expose much more of you and Eugene and your PP's. One last thing tell ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities